SINGLE-CENTER EXPERIENCE WITH LEVOSIMENDAN AS AN ALTERNATIVE TO CATECHOLAMINE IN CHILDREN WITH SEVERE CATECHOLAMINE DEPENDENT END-STAGE HEART FAILURE

F Atshome. Louis Pradel Hospital, Lyon, France

**Objective** To describe our preliminary experience with Levosimendan during the last 4 years, a new calcium-sensitizing agent in critically unwell infants and children with severe heart failure.

**Design** Retrospective cohort analysis.

**Setting** Pediatric cardiology intensive care unit.

**Patients** 8 children aged 2.5 months to 13 yrs (median age 44 months) with severe myocardial dysfunction secondary to endstage heart failure who were inotropic dependent (requiring at least one catecholamine).

**Interventions** A single dose (continuous intravenous infusion over 24 hrs) of Levosimendan was given under continuous hemodynamic monitoring in our intensive care unit.

Six children received a single dose, two children received two doses.

Echocardiographic assessments of ventricular function were made before and 3-5 days after Levosimendan infusion.

**Main Results** Heart rate, systolic pressure, diastolic pressure, mean blood pressure, shortening fraction, the dose of inotrope at the beginning of levosimendan infusion, at 24 hours and 36 hours, ECG result 24 hour after levosimendan infusion.

**Conclusions** Levosimendan appeared to be a safe and efficacious drug when given to children with uncompensated end-stage heart failure in this size-limited sample. It warrants formal prospective large-cohort evaluation and multicenter trial to determine its safety profile and clinical application in the pediatric population.

LOW PLATELET COUNT IS ASSOCIATED WITH DUCTUS ARTERIOSUS PATENCY IN PRETERM NEWBORNS

E Alyamac Dizard, R Ozdemir, FN Sari, S Yurtutan, T Gokmen, O Erdevi, FE Canpolat, N Uras, SS Ugur, U Dilmen. Neonatal Intensive Care Unit, Zekai Tahir Burak Maternity and Teaching Hospital, Ankara, Turkey

**Background and Aims** To determine whether there is an association between platelet counts and patent ductus arteriosus (PDA) incidence and/or closure in preterm newborns.

**Methods** Premature infants with hemodynamically significant PDA (n=154) and a control group without PDA (n=207) who were hospitalized in the NICU were eligible. Platelet counts and other platelet indices including mean platelet volume (MPV) and platelet distribution width (PDW) of the infants in both groups during the first 5 days of life were recorded. Ibuprofen was started in infants with hemodynamically significant PDA and echocardiography was repeated 48 hours thereafter to assess the closure of ductus.

**Results** Median gestational age and birth weight of the infants with PDA were 28 (range 26–29) and 1060 (range 892–1250) gr respectively. Platelet counts were significantly lower in the patient group than in the control group (p<0.001). Multivariate analysis including gestational age, presence of RDS, presence of thrombocytopenia and PDW showed that platelet count < 150,000 (OR=2.13, 95% CI 1.26–3.61, p=0.005), high PDW (>17) (OR=2.68, 95% CI 1.41–5.09, p=0.003) and the presence of RDS (OR=2.25, 95% CI 1.41–3.59, p=0.001) were independently associated with higher risk of hemodynamically significant PDA. Baseline platelet counts of the infants in whom ductus closed or persisted after ibuprofen treatment were similar.

**Conclusions** Low platelet count was associated with ductus arteriosus patency in preterm infants while other platelet indices were not. We could not show an association between platelet counts and persistence or closure after medical treatment.

WHAT IS THE EFFECT PDA AND ITS MEDICAL CLOSURE ON CEREBRAL AND ABDOMINAL TISSUE OXYGENATION IN PRETERM NEWBORNS?

E Ergenelen, I Hifringolu, S Beken, N Altuntas, E Karanci, S Unal, F Kulali, S Aktaş, E Oral, C Türkylmaz, E Koc, Y Atalay. Pediatrics/Newborn Medicine, Gazi University Hospital, Ankara, Turkey

**Background and Aims** Patent ductus arteriosus (PDA) is a frequent problem in preterms known to have significant effects on organ perfusion. The aim of this study was to investigate the difference between cerebral and abdominal tissue oxygenation index (TOI) measured by near infrared spectroscopy (NIRS) before and after treatment of hemodynamically significant PDA in preterm newborns.

**Methods** Cerebral and abdominal TOI were recorded by NIRS (NIRO 200 Hamamatsu, Japan) in preterm newborns with hemodynamically significant PDA requiring ibuprofen treatment. Newborns with congenital anomalies were excluded. 20 minute recordings were obtained before treatment and after documented ductal closure by echocardiography as well as real time oxygen saturation (SaO₂) monitoring by pulse oxymetry. Fractional tissue oxygen extraction (FTOE) was calculated using TOI and SaO₂.

**Results** Fourteen newborns were included, abdominal recordings were available in 13. Mean BW and GA were 1089 and 29 weeks respectively. No change was observed in cerebral or abdominal tissue oxygenation and oxygen extraction before and after medical closure of PDA. Pre and posttreatment cerebral TOI values (median and range) were 67.17 (50.9–89.1) and 64.55 (54.9–87.4) P=0.3, and pre and posttreatment cerebral FTOE values were 0.3 (0.03–0.45) and 0.29 (0.05–0.42) P=0.09 respectively. Pre and posttreatment abdominal TOI values were (median and range) 53.9 (40.1–62.9) and 50.29 (39.2–78.5) P=0.7, pre and posttreatment abdominal FTOE values were 0.44 (0.32–0.59) and 0.46 (0.2–0.6) P=0.8 respectively.

**Conclusion** Results of this small group may suggest that cerebral and abdominal tissue oxygenation is preserved during hemodynamically significant PDA, however more detailed studies are warranted.

FETAL HYPOXIA-ISCHEMIA IS RELATED TO CIRCULATORY COMPROMISE IN PRETERM INFANTS

1DC Vlijbrief, 1MJNL Benders, 2H Kemperman, 1F van Bel, 1WB de Vries. 1Neonatology; 2Clinical Chemistry and Hematology, Wilhelmina Children’s Hospital/University Medical Center Utrecht, Utrecht, The Netherlands

**Background and Aims** Impairment of gas exchange and blood flow through the placenta leads to hypoxia and hypercapnia. This causes increased systemic vascular resistance and tachycardia, thus compromising the cardiovascular system of the foetus. The biomarker B-type natriuretic peptide (BNP) can be used to identify significant cardiovascular compromise in infants. The aim of the present study was to investigate whether BNP can be used to identify those preterm infants with significant cardiovascular compromise during periparturient period.

**Methods** In this retrospective cohort study all infants born after a gestational age of less than 32 weeks were evaluated. Maternal, fetal and infant factors associated with prenatal and perinatal hypoxia-ischemia were related to BNP levels after birth. Pathologic examination of the placenta was routinely performed.